Wednesday, July 8, 2026

pharma · Advanced Cancer · Non-small Cell Lung Cancer · RCUS

Arcus Biosciences

Arcus Biosciences clinical programs — 53 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

3928 Point Eden Way, Hayward, California 94545, US HQ
2015 Founded
655 Employees
Public company Type
RCUS · NYSE Ticker
Company details
Status
Public
HQ
3928 Point Eden Way, Hayward, California 94545, US
Founded
2015
Employees
655
Programs
53
Drugs
25
Patents
30
Intelligence · Clinical Programs

Arcus Biosciences projects

53 ClinicalTrials.gov programs sponsored by Arcus Biosciences.

Arcus Biosciences has 53 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

Page 2 of 2
  1. [14C]-etrumadenant

    Arcus Biosciences

    Healthy Participants

    phase 1 small molecule completed

    1 trial
  2. casdatifan

    Arcus Biosciences

    Clear Cell Renal Cell Carcinoma

    phase 1 small molecule active

    1 trial
  3. etrumadenant

    Arcus Biosciences

    GastroEsophageal Cancer

    phase 1 small molecule completed

    1 trial
  4. zanzalintinib

    Arcus Biosciences

    Advanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid Tumors

    phase 1 small molecule terminated

    1 trial
  5. zimberelimab

    Arcus Biosciences

    Advanced Solid Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Arcus Biosciences have?

53 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.